

# DAY ONE: WEDNESDAY

07.00	Registration						
07.00-08.00	Nurses Breakfast						
08.30-09.45	Opening Ceremony						
08.30 - 08.40	<b>Welcome to the Conference</b> Philip Bruggmann, Arud, Centre for Addiction Medicine, Switzerland						
08.40 - 08.45	<b>Welcome</b> Ruth Dreifuss, Global Commission on Drug Policy, and Past President Switzerland						
08.45 - 08.50	<b>The global picture of health for people who use drugs</b>						
08.50 - 08.55	<b>Global Fund's commitment to financing harm reduction and healthcare provision</b>						
08.55 - 09.00	<b>UNODC support of health-based drug policies and harm reduction</b>						
09.00 - 09.05	<b>Investing in harm reduction approaches to treat and prevent hepatitis C</b>						
09.05 - 09.10	<b>Community Opening</b>						
09.10 - 09.20	<b>Awards</b>						
09.20 - 09.35	<b>Global, regional, and country-level coverage of testing and treatment for hiv and hepatitis c infection among people who inject drugs: a systematic review</b> Behzad Hajarizadeh, The Kirby Institute, UNSW Sydney, Australia						
09.35 - 09.50	<b>Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies</b> Louisa Degenhardt, NDARC UNSW, Australia						
09.45 - 10.30	Coffee Break						
10.30 - 12.00	Plenary Session B: Leveraging funding opportunities to improve the health of people who use drugs						
10:30 - 10:45	<b>Understanding the gaps in healthcare provision for people who use drugs</b> Niklas Luhmann, WHO, Switzerland						
10:45 - 11:00	<b>Funding landscape for viral hepatitis and harm reduction</b> Naomi Burke Shyne, Executive Director, Harm Reduction International						
11:00 - 11:10	<b>Egypt Case Study: using HCV elimination to increase access to harm reduction</b>						
11:10 - 11:20	<b>Ukraine Case Study: using funding opportunities to improve health and services for people who use drugs</b>						
11:20 - 12:00	<b>Panel Discussion: Opportunities for leveraging funding to improve the health of people who use drugs</b> Finn-Jarle Rode, Executive Director, The Hepatitis Fund Umesh Chawla, Lead Key Populations, CHAI Susie McClean, The Global Fund, Switzerland						
12.00 - 13.45	Lunch						
13:45 - 15:00	<b>Session C Abstract Session: Infectious diseases and harm reduction</b>	13:45 - 15:00	<b>Session D Abstract Session: Drug treatment and harm reduction services</b>	13:45 - 15:00	<b>Session E Abstract Session: Hepatitis C testing and linkage to care</b>	13:45 - 15:00	<b>Session F Workshop: A toolkit for integrating research into community based settings for people who use drugs</b>
15:00 - 15:45	CATIE: Canadian Networking Event						
15:00 - 15:45	Coffee Break & Poster Tour						
15.10-15.35	<b>Poster Tour 01: HCV treatment uptake, co-morbidities, and mortality: What are the current research gaps?</b>		15.10 - 15.35	<b>Poster Tour 02: Integrated care models and programs: What's working? What's not?</b>		15.10 - 15.35	<b>Poster Tour 03: HIV infection among people who inject drugs</b>
15.45 - 17.15	<b>Session G: Big events: Implications for people who use drugs</b>	15.45 - 17.15	<b>Session H: Successes in harm reduction implementation: Lessons from Switzerland</b>	15.45 - 17.15	<b>Session I: Monitoring viral hepatitis and HIV among PWID: models of observational studies in Europe (EMCDDA)</b>  This session will present state of the art observational studies conducted in Europe to monitor the prevalence of viral hepatitis, HIV, risk factors and interventions among PWID and discuss lessons learned.	15.45 - 17.15	<b>Session J INHSU EMCR Workshop: Making your research matter: Collaborating with governments and NGOs</b>
15:45-16:05	<b>Harm reduction and BBV care during wartime in Ukraine</b> Iryna Ivanchuk, Public Health Center MOH, Ukraine	15:45 - 16:05	<b>Harm reduction in Switzerland: lessons learned and future challenges</b> Barbara Broers, University of Geneva, Switzerland				1. Provide an opportunity for EMCRs to meet experts working in public health and policy  2. Stimulate discussion on opportunities/strategies for EMCRs to initiate/sustain collaboration with government and NGOs in diverse sectors to produce innovative research to inform clinical, public health or policy guidance.  3. Provide information about career options outside traditional academic settings.
16:05-16:25	<b>Pandemics</b>	16:05-16:25	<b>Integrated OAT care – the example of integrating female health</b> Lina Hijazi, Arud, Switzerland				
16:25-16:45	<b>Impact of Migration on Drug Use and Access to Services</b> Ancella Voets, Mainline, Netherlands	16:25-16:45	<b>Psychedelics in addiction therapy</b> Louise Penzenstadler, University of Geneva, Switzerland				
16.45 - 17.15	<b>Questions &amp; Discussion</b>	16.45 - 17.15	<b>Questions &amp; Discussion</b>				
17.15 - 17.20	Room Movement						
17.20 - 18.00	Session with the Global Commission on Drug Policy						
18.00 - 19.30	Welcome Reception & Poster Viewing						

# DAY TWO: THURSDAY



07.30 - 08.00	Registration						
08.00 - 08.45	AbbVie Sponsored Morning Symposium						
8.30 - 10.30	Session K: Health service delivery in prisons						
09:00 - 09:15	<b>Enhancing BBV, harm reduction and health service coverage in prisons</b> Rick Altice, Yale University School of Medicine, USA						
09:15 - 09:30	<b>Global best practice examples of prison-based models of care</b> Joaquin Cabezas, University Hospital Marques De Valdecilla, Spain						
09:30 - 09:45	<b>Community-led models for improving care in prisons: successes and challenges</b> Julia Sheehan, Hep C Trust, UK						
09.45 - 10.00	Questions & Discussion						
10.00 - 10.15	<b>Criminalisation of drug use: Voices from people who Inject Drugs</b> Marie Jauffret-Routsid, INSERM, France						
10.15 - 10.30	<b>Peer-Facilitated Telemedicine Hepatitis C Treatment For Rural People Who Use Drugs: Results From A Randomized Controlled Trial</b> Andrew Seaman, Oregon Health And Sciences University / Central City Concern, United States						
10.30 - 11.15	Coffee Break & Poster Tour						
10.40 - 11.05	Poster Tour 04: Improving healthcare in prison: HCV, HBV, HIV, and OAT	10.40 - 11.05	Poster Tour 05: Applying big ideas to improve health equity for people who inject drugs	10.40 - 11.05	Poster Tour 06:		
11.15 - 12.15	<b>Plenary Session L: Panel Discussion. Surfacing productive difference: Recognising diverse perspectives of drug use, harm reduction, and drug policy</b> Alison Ritter, The University of New South Wales, Australia						
12.15 - 14.00	Lunch						
12.45 - 13.45	Gilead Sponsored Lunch Symposium						
14.00 - 15.20	Session M Abstract Session: Prison based research and service delivery	14.00 - 15.10	Session N Abstract Session: Community involvement and peer-led models	14.00 - 15.00	Session O Abstract Session: Hepatitis models of care	14.00 - 15.00	Session P: Workshop: Catalyzing collaboration between communities and legislators to ensure access to health for all (UNITE)
15.00 - 15.45	Coffee Break						
15.45 - 17.15	Session Q: Hepatitis C: elimination progress, testing innovations, advanced liver disease management	15.45 - 17.15	Session R: INHSU Prisons 'Hypothetical': hepatitis C services in prisons	15.45 - 17.15	Session S: Introducing innovative harm reduction tools: an update on Unitaids' plans	15.45 - 17.15	Session T: Knowledge exchange on Drug Consumption Rooms (DCR): different models and good practices in Europe
15.45 - 16.05	Innovations in HCV testing and practical implications for enhancing care Jordan Feld, University Health Network, Canada			15.45 - 15.52	Overview of strategic area and work proposed on HCV prevention in key populations		
16.05 - 16.25	Monitoring and measuring progress towards hepatitis C elimination Olufunmilayo Lesi, Afro Hepatitis Focal Point, Congo			15.52 - 15.59	Involving communities: creation of a Community Advisory Board Annie Madden, INPUD		
16.25 - 16.45	Prevention and management of advanced liver disease (including late-presentation) Mark Sonderup, University of Cape Town, South Africa			15.59 - 16.24	Proposed research to enable access to key innovations (LA Buprenorphine) for key populations		
16.45 - 17.15	Questions & Discussion			16.24 - 16.49	Proposed research to enable access to key innovations (low dead-space syringes) for key populations		
			Based on the patient journey, this session will dramatize the decision-making process in the course of implementation or scale up of hepatitis C services in prisons.	16.49 - 17.15	Questions & Discussion		This workshop will discuss models of DCRs and good practices related to services from different European countries and contexts.
18.30 - 23.00	Conference Dinner						

# DAY THREE: FRIDAY

09.15 - 11.00	Session U: Women who use drugs						
09.15 - 09.20	Jude Byrne Award Introduction						
09.20 - 09.25	Jessica Inés Morales Garay LANPUD, Guatemala						
09.25 - 09.30	Kira Watson Crew 2000, United Kingdom						
09.30 - 09.45	Woman and drugs in context: understanding the role of gender in drug use Nuria Romo, University Of Granada, Spain						
09:45 - 10:00	Community responses to gender-based inequities: improving visibility and facilitating access to services/resources Rita Gatonye, Women In Response To Hiv/aids And Drug Addiction, Kenya						
10:00 - 10:30	Questions & Discussion						
10.30 - 10.45	A national program to scale-up decentralized hepatitis C virus point-of-care testing and treatment in Australia Jason Grebely, The Kirby Institute, UNSW Sydney, Australia						
10.45 - 11.00	HIV treatment outcomes among people who inject drugs: A global systematic review and meta-analysis Kennedy Kipkoech, University of Cape Town, UK						
11.00 - 11.30	Coffee Break						
11.30 - 12.30	Session V Abstract Session: HCV treatment	11.30 - 12.30	Session W Abstract Session: Drug use trends, policy and practice	11.30 - 12.35	Session X Abstract Session: Reducing harms that may relate to drug use	11:30 - 12:30	Session Y Nurses Workshop: Balancing Individual and Population Health: Novel Approaches to Testing for Blood Borne Viruses and STIs Among People Who Use Drugs
12.30 - 13.30	Lunch						
12.50-13.20	UNODC Gender Based Violence Report						
13.30 - 15.00	Session Z: Harm reduction interventions: approaches, coverage, and innovations	13.30 - 15.00	Session ZA: Community-led initiatives to enhance access to services for people who use drugs	13.30 - 15.00	Session ZB: Women who Inject Drugs in Europe: specific challenges for interventions (EMCDDA)	13.30 - 15.00	Session ZC Workshop: How can we expand prison peer programmes? Lessons from England and ideas for future models (Hep C Trust)
13.30 - 13.50	Harm reduction for stimulant use Ernesto Cortes, LANPUD, Costa Rica		This session will discuss; how to build a strong foundation to support CLM, how to ensure community independence, how to build strong partnerships to support CLM.		The session will describe the profile of women who inject drugs, describe their gender responsive interventions, and present examples of good practice.		This workshop aims to share experiences of establishing a highly successful PP Program, catalyze debate around the potential for these, and increase momentum in implementing global PP models.
13.50 - 14.10	Safer supply: models, examples, nuances Gillian Kolla, University Of Victoria, Canada						
14.10 - 14.30	Drug-checking services: state of the art on approaches and data trends Dominique Schori, Drug Information Center (DIZ), Switzerland						
14.30 - 15.00	Questions & Discussion						
15.00 - 15.30	Coffee Break						
15.30 - 16.30	Conference Closing						